BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Expected to Earn FY2022 Earnings of $1.10 Per Share

BioMarin Pharmaceutical Inc. (NASDAQ:BMRNGet Rating) – Cantor Fitzgerald issued their FY2022 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a research note issued on Thursday, August 4th. Cantor Fitzgerald analyst O. Brayer anticipates that the biotechnology company will earn $1.10 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $110.00 price objective on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $0.95 per share.

Other equities analysts also recently issued reports about the company. Wedbush reissued a “hold” rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, June 24th. Credit Suisse Group upped their target price on BioMarin Pharmaceutical from $105.00 to $106.00 and gave the company an “outperform” rating in a research report on Monday, June 6th. Barclays upped their target price on BioMarin Pharmaceutical from $112.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday. Jefferies Financial Group reaffirmed a “buy” rating and set a $100.00 price target on shares of BioMarin Pharmaceutical in a research report on Wednesday, May 4th. Finally, SVB Leerink increased their price target on BioMarin Pharmaceutical from $115.00 to $122.00 and gave the stock an “outperform” rating in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $110.40.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN stock opened at $95.82 on Friday. The business’s fifty day simple moving average is $82.81 and its 200-day simple moving average is $82.21. The company has a market cap of $17.73 billion, a PE ratio of 368.55, a PEG ratio of 1.86 and a beta of 0.33. The company has a current ratio of 4.88, a quick ratio of 3.28 and a debt-to-equity ratio of 0.25. BioMarin Pharmaceutical has a 12-month low of $70.73 and a 12-month high of $96.50.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Rating) last posted its earnings results on Wednesday, August 3rd. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.04. BioMarin Pharmaceutical had a return on equity of 1.80% and a net margin of 2.83%. During the same quarter last year, the company earned $0.23 earnings per share.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 7,398 shares of the stock in a transaction dated Friday, July 8th. The shares were sold at an average price of $90.00, for a total value of $665,820.00. Following the completion of the sale, the executive vice president now owns 58,941 shares in the company, valued at approximately $5,304,690. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Brian Mueller sold 7,337 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, July 8th. The shares were sold at an average price of $89.50, for a total value of $656,661.50. Following the completion of the sale, the chief financial officer now owns 30,726 shares in the company, valued at approximately $2,749,977. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP George Eric Davis sold 7,398 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, July 8th. The shares were sold at an average price of $90.00, for a total transaction of $665,820.00. Following the completion of the sale, the executive vice president now owns 58,941 shares of the company’s stock, valued at approximately $5,304,690. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,043 shares of company stock worth $1,425,735. Insiders own 1.75% of the company’s stock.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in BMRN. Norges Bank purchased a new stake in shares of BioMarin Pharmaceutical during the 4th quarter worth $207,582,000. Adage Capital Partners GP L.L.C. lifted its position in shares of BioMarin Pharmaceutical by 372.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,865,000 shares of the biotechnology company’s stock worth $164,773,000 after purchasing an additional 1,470,498 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in shares of BioMarin Pharmaceutical during the 4th quarter worth $104,253,000. Viking Global Investors LP lifted its position in shares of BioMarin Pharmaceutical by 30.7% during the 1st quarter. Viking Global Investors LP now owns 3,752,393 shares of the biotechnology company’s stock worth $289,310,000 after purchasing an additional 882,446 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in shares of BioMarin Pharmaceutical during the 4th quarter worth $48,817,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

BioMarin Pharmaceutical Company Profile

(Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

See Also

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.